← Holders
Davern Capital Partners, LP
What Davern Capital Partners, LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2003147 · Filed Nov 12, 2026
- Positions
- 17
- Reported value
- $514.1M
- Opened
- 5
- Closed
- 3
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Dec 31, 2025$309.3M14 positions
- Mar 31, 2026$364.5M17 positions
- Jun 30, 2026$586.5M15 positions
- Sep 30, 2026$514.1M17 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
BNTXBioNTech SE | 682.1K | −9.6% | $67.1M | 13% |
RPRXRoyalty Pharma plc | 974.4K | −15.7% | $56.9M | 11.1% |
INSMInsmed Inc | 496K | −11.4% | $56.6M | 11% |
ROIVRoivant Sciences Ltd. | 1.5M | −23.8% | $53.9M | 10.5% |
IONSIonis Pharmaceuticals Inc | 1.1M | +36.1% | $48.5M | 9.4% |
ARGXArgenx SE | 37.6K | New | $36.1M | 7% |
REGNRegeneron Pharmaceuticals, Inc. | 40.7K | −56.1% | $30.8M | 6% |
NTRANatera, Inc. | 63.2K | −46.9% | $26.1M | 5.1% |
ABVXAbivax S.A. | 219.2K | New | $21.7M | 4.2% |
VERAVera Therapeutics, Inc. | 628.3K | +25.9% | $20.3M | 3.9% |
MLYSMineralys Therapeutics, Inc. | 695.2K | −19.1% | $17.5M | 3.4% |
LEGNLegend Biotech Corp | 828.9K | −30.4% | $16.5M | 3.2% |
ARWRArrowhead Pharmaceuticals, Inc. | 229.3K | New | $15M | 2.9% |
LLYEli Lilly & Co | 12.6K | New | $14.6M | 2.8% |
GENBGenerate Biomedicines, Inc. | 824.7K | ±0% | $12.4M | 2.4% |
VRDNViridian Therapeutics, Inc. | 560.7K | New | $11.5M | 2.2% |
AVTXAvalo Therapeutics, Inc. | 564.4K | +20.4% | $8.7M | 1.7% |